<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935190</url>
  </required_header>
  <id_info>
    <org_study_id>CP001</org_study_id>
    <nct_id>NCT04935190</nct_id>
  </id_info>
  <brief_title>Comparison of Resting Heart and Respiratory Rate Measurements Acquired by Contactless Radar Sensors, Electrocardiography, and Capnography</brief_title>
  <acronym>Vitalpercept</acronym>
  <official_title>Comparison of Resting Heart and Respiratory Rate Measurements Acquired by Contactless Radar Sensors, Electrocardiography, and Capnography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DawnLight</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DawnLight</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Determine agreement (accuracy) of resting heart rate measured by Vitalpercept when&#xD;
           compared to an FDA-cleared electrocardiograph (ECG) device, LifeSignals Wireless&#xD;
           Biosensor.&#xD;
&#xD;
        2. Determine agreement (accuracy) of resting respiratory rate measured by Vitalpercept when&#xD;
           compared to an FDA-cleared capnographer, Capnostream 20.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events</measure>
    <time_frame>During Data collection-Expected time=45-60 minutes</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Heart Rate</measure>
    <time_frame>During Data collection-Expected time=45-60 minutes</time_frame>
    <description>Effectiveness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Respiratory Rate</measure>
    <time_frame>During Data collection-Expected time=45-60 minutes</time_frame>
    <description>Effectiveness</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vital Signs</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition will be assigned to Group 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vitalpercept</intervention_name>
    <description>Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition&#xD;
        (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1.&#xD;
&#xD;
        Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition will&#xD;
        be assigned to Group 2.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects â‰¥ 21 years of age at the time of signing the informed consent.&#xD;
&#xD;
          2. Subjects willing to sign the informed consent and capable of committing to the&#xD;
             duration of the study.&#xD;
&#xD;
          3. Subjects with the ability to lie flat, lie on left side, lie on right side, and sit in&#xD;
             a chair.&#xD;
&#xD;
          4. Subjects who are able to breathe through their nose for the capnography assessment.&#xD;
&#xD;
          5. Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition&#xD;
             (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1.&#xD;
&#xD;
          6. Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition&#xD;
             will be assigned to Group 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are prone to excessive coughing and excessive movement&#xD;
&#xD;
          2. Subjects who have a condition that involves uncontrollable movement of the body such&#xD;
             as Parkinson's Disease or Essential Tremor.&#xD;
&#xD;
          3. Subjects with a history of allergy to adhesive, latex or Nuprep.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

